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Abstract Chronic recurrent multifocal osteomyelitis
(CRMO), also known as chronic non-bacterial
osteomyelitis (CNO), is a rare inflammatory disorder that
primarily affects children. It is characterized by pain, local
bone expansion, and radiological findings suggestive of
osteomyelitis, usually at multiple sites. CRMO predomi-
nantly affects the metaphyses of long bones, but involve-
ment of the clavicle or mandible are suggestive of the
diagnosis. CRMO is a diagnosis of exclusion, and its
pathogenesis remains unknown. Differential diagnosis
includes infection, malignancies, benign bone tumors,
metabolic disorders, and other autoinflammatory disorders.
Biopsy of the bone lesion is not often required but could be
necessary in unclear cases, especially for differentiation
from bone neoplasia. Non-steroidal anti-inflammatory
drugs (NSAIDs) are the first-line treatment. Alternative
therapies have been used, including corticosteroids,
methotrexate, bisphosphonates, and tumor necrosis factor
(TNF)-a inhibitors. No guidelines have been established
regarding diagnosis and treatment options. This manuscript
gives an overview of the most recent findings on the
pathogenesis of CRMO and clinical approaches for patients
with the condition.
Key Points
• Chronic recurrent multifocal osteomyelitis is a
chronic autoinflammatory bone disease that is
usually benign except for when the spine is involved.
• Therapy needs to be better defined, but non-
steroidal anti-inflammatory drugs are the current
first-line treatment. Bisphosphonates are a good
option for patients with spine involvement, and
tumor necrosis factor-a inhibitors may be useful in
patients with systemic features.
1 Introduction
Autoinflammatory bone diseases include a spectrum of
disorders characterized by spontaneous activation of the
innate immune system that leads to bone inflammation.
These diseases have attracted medical attention in recent
years and have been found to be associated with other
clinical features and/or with autoinflammatory syndromes
[1]. The most well understood autoinflammatory bone
disorder is chronic non-bacterial osteomyelitis (CNO),
which is characterized by the presence of one or more
aseptic osteomyelitis lesions. Some authors prefer the term
chronic recurrent multifocal osteomyelitis (CRMO) [2–4]
because of the presence of multiple bone lesions and the
recurrent nature of the disease. The two terms may be used
interchangeably.
CRMO is a rare non-infectious inflammatory bone dis-
ease characterized by recurrent bone pain. It affects mostly
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2children and adolescents, with a male: female ratio of 1:4
and an average age at time of diagnosis of 10 years. This
clinical entity was described for the first time in 1972 by
Giedion et al. [2] as an unusual form of symmetrical,
chronic multifocal osteomyelitis with bone lesions. Many
clinical series have been published since then, but the
disease is still considered rare, with a prevalence ranging
from 1:160,000 to 1:2,000,000 and an annual incidence of
1:250,000 to 1:1,000,000. However, the prevalence of
CRMO is probably underestimated; a single-center retro-
spective study recently suggested its incidence may be
comparable with that of infectious bone osteomyelitis [5].
The main aim of this review was to provide an update on
the pathogenesis of and treatment options in CRMO for
pediatricians dealing with inflammatory bone disorders.
2 Pathogenesis and Genetics
The etiology of CRMO is still debated. It has been
demonstrated that infections are not involved in disease
etiology: wide microbiological analysis results were con-
sistently negative, and the ineffectiveness of antibiotics in
treating CRMO supports this hypothesis [6].
It has been suggested that imbalance between pro-in-
flammatory cytokines (e.g., interleukin [IL]-6, IL-1b, tumor
necrosis factor [TNF]-a) and anti-inflammatory cytokines
(e.g., IL-10) may be centrally involved in CRMO patho-
genesis [6] because these molecules play a role in bone
resorption and remodeling through the activation of osteo-
blast and osteoclasts. Moreover, peripheral blood mononu-
clear cells from patients with CRMO in active disease
stimulated in vitro with lipopolysaccharide (LPS) showed a
significant increase in IL-1b release compared with healthy
control cells, and immunohistochemistry staining of bone
tissue revealed the expression of inflammasome components
in CRMO osteoclasts [7]. Similar results suggesting reduced
IL-10 and IL-19 expression and enhanced IL-20 expression
in CRMO monocytes have been reported [8].
The presence of chronic aseptic osteomyelitis in some
syndromes characterized by inflammasome alterations,
such as Majeed syndrome [1], cherubism [9], hypophos-
phatasia [10], and primary hypertrophic osteoarthropathy
[11], have also led to suggestions that CRMO may itself be
considered an autoinflammatory disease. In addition,
chronic osteomyelitis is a feature of PAPA (pyogenic
arthritis, pyoderma gangrenosum, and acne) syndrome, an
autosomal-dominant genetic disease caused by mutations
of the cluster of differentiation (CD)-2 binding protein 1
(CD2BP1) gene, which is involved in bone inflammatory
pathways [12].
Similarly, sterile multifocal osteomyelitis, periostitis,
and pustulosis are present from birth in DIRA (deficiency
of the IL-1–receptor antagonist), a rare autosomal-reces-
sive disease resulting from mutations in the IL1RN gene
encoding the IL-1 receptor antagonist [13].
Evidence for a genetic basis is also present in non-
syndromic or sporadic CRMO [14]. In fact, the prevalence
of inflammatory bone disease among patients’ relatives
varied between 12 and 32% in large cohorts of patients
with CRMO [15], and several reports described families
with multiple affected members [16] or a high incidence of
psoriasis, inflammatory bowel disease, and other chronic
inflammatory conditions in first-degree relatives [17]. This
suggests a continuum between autoinflammation and
autoimmunity. Additional evidence of a possible genetic
contribution to the disease comes from studying the role of
IL-10 in disease pathogenesis. One small study reported an
association between CRMO and polymorphisms of the IL-
10 promoter, and functional data suggest that IL-10
deregulation may play a role in disease pathogenesis
[18, 19]. It was recently demonstrated that impaired
mitogen-activated protein kinase (MAPK) signaling,
reducing H3S10 phosphorylation and Sp1 recruitment to
the IL-10 promoter, may lead to impaired gene expression,
confirming a role for IL-10 [19].
Finally, homozygous mutation of the pstpip2 gene in
mice results in an autoinflammatory disease very similar to
human CRMO [20, 21]. However, candidate genes,
including PSTPIP1, CARD15/NOD2, and IL1RN, were not
associated with CRMO in humans when analyzed in small
cohorts [22, 23].
3 Clinical Presentation
CRMO is characterized by bone pain with insidious onset.
Soft tissue swelling may accompany pain but is not nec-
essarily always present. In about 30% of patients, adjacent
joints are involved with articular effusions, synovial
hypertrophy, and cartilage damage [5]. The lesions can
affect any bone segment, but the more frequently reported
locations include metaphyses of long bones (especially
distal femur, proximal and distal tibia, and fibula), followed
by pelvis, clavicle, and spine [15]. Involvement of the
sternum, clavicle, or jaw is very suggestive of CRMO,
whereas the skull is very rarely involved. Systemic symp-
toms are subtle and may include low-grade fever, malaise,
or poor growth. Extra-articular manifestations include the
skin (especially psoriasis, pustulosis of palms and soles,
and acne) and intestines, most often Crohn’s disease and
less frequently ulcerative colitis [24]. In particular, 20% of
patients with CRMO present with an inflammatory disease
of the skin or intestines [5].
In adults, SAPHO syndrome is the combination of
synovitis, acne, pustulosis of palms and soles, hyperostosis,
3and osteitis and appears to be a more severe clinical picture
of CRMO that occurs later in life [25].
Laboratory tests can show leukocytosis and raised
inflammatory markers, but these findings are also fre-
quently absent.
The clinical course is chronic with periods of relapse and
even long periods of clinical remission. Prognosis depends
on the severity of inflammation and the site of bone
involvement. It has been reported that the disease can resolve
completely in a median time of 7–20 years [26–29]. How-
ever, sequelae, from mild to debilitating, have been descri-
bed in a considerable percentage of cases (up to 50% in some
series), with the most common complications described
being leg–leg discrepancy, kyphosis, vertebral collapse,
growth arrest, and early closing of growth plates [5, 30].
As mentioned, CRMOmay be a clinical feature of genetic
autoinflammatory diseases. For instance, CRMO may be a
distinctive feature of Majeed syndrome, an autosomal reces-
sively inherited disease characterized by a more severe phe-
notype than CRMO. The onset of symptoms is usually in
infancy or within the first 2 years of life, while chronic
inflammatory osteomyelitis typically involves the small bones
of the hands and feet and the metaphyses of long bones. The
distinctive clinical course includes flares of bone pain and
fever[38.5 C for 3–4 days, recurring every 2–4 weeks and
is associated with dyserythropoietic anemia [1].
In patients with DIRA, bone involvement includes
multifocal osteolytic lesions and periosteal elevation along
the metaphysis of multiple long bones. Involvement of the
spine and skull has also been reported. Heterotopic ossifi-
cation may occur around the hip and proximal femur.
Epiphyseal ballooning of anterior ribs occurs in nearly
100% of affected infants. In these cases, the age of onset is
very early, usually in the first weeks of life; disease onset is
very severe, with joint swelling, a pustular rash, and pain
on palpation of long bones [13].
Almost all patients with genetic forms of CRMO present
with elevated inflammatory markers.
4 Diagnosis
No consensus exists on CRMO diagnosis, which is based
on clinical, laboratory, and radiologic findings. Laboratory
tests are fairly non-specific: blood count is usually normal,
whereas inflammatory markers are generally only moder-
ately increased, except for patients with associated sys-
temic features such as fever [5].
4.1 Imaging Assessment
Plain X-rays are the first-line diagnostic investigation in a
child with bone pain, albeit results can be normal in the
early stages of disease. The first radiological findings are
typically modifications in bone metaphyses, especially in
close proximity to growth plates. Osteolytic and sclerotic
lesions may be discovered, generally in the absence of
periosteal reaction, in late stages of disease [31]. However,
these findings are not mandatory, and other reports have
shown radiological discontinuation of cortical bone.
Computer tomography (CT) scans usually provide better
radiologic definition of bone structures. However, to limit
radiation exposure, it is used only in cases where the
diagnostic doubt remains very high. CT scans can also
highlight the thickening of cortical bones, the areas of lysis
mixed with sclerosis, and soft tissue edema (Fig. 1). All
these radiological findings are very suggestive of CRMO.
The involvement of metaphyses and of multiple local-
izations are suggestive of CRMO. Thus, whole-body
magnetic resonance imaging (MRI) is becoming increas-
ingly important as it enables the easy identification of
multiple bone lesions and inflammatory features such as
soft tissue edema. It is probably more sensitive than bone
scintigraphy [32]. CRMO inflammatory lesions produce an
image with T1-weighted hypointensity, whereas a high
signal appears in T2-weighted images [31] (Fig. 2). The
lack of radiation is a further advantage of MRI over CT.
MRI is also considered the best radiologic option, espe-
cially in the beginning of the disease compared with CT.
4.2 The Role of Biopsy
The role of bone biopsy is still debated as histologic fea-
tures are non-specific; however, it plays an important role
in ruling out malignancies, especially in cases with single
bone lesions [31]. Histologic findings include inflammatory
infiltrates comprising lymphocytes, plasma cells, histio-
cytes, and neutrophils. Immunohistochemistry demon-
strates the predominance of CD8? T cells (TCD8?):
CD3? , CD45RO? , CD20? , and CD68? macrophages
[3]. In the early phases of the disease, innate immune
activation, with the presence of neutrophils, is predomi-
nant, whereas, in the later stages of the disease, monocytes,
macrophages, lymphocytes, and plasma cells (as expres-
sion of adaptive immunity involvement), as well as oste-
olysis, sclerosis, and/or fibrosis, can be detected [33].
Given the complexity of the clinical picture, CRMO
clinical diagnostic criteria have been proposed.
Jansson et al. [24] conducted a retrospective study to
assess data on patients from a pediatric clinic and an
orthopedic tertiary care clinic. Patients aged[3 years
(n = 224) with either CRMO, proven bacterial
osteomyelitis, malignant bone tumors, or benign bone
tumors were identified. Univariate logistic regression was
used to determine associations between single risk factors
and a diagnosis of CNO, and multivariable logistic
4regression was used to assess simultaneous risk factor
associations with CRMO. Based on these criteria, the
diagnosis may be fulfilled if at least two major criteria, or
one major plus two minor criteria, are present [24]. The
major criteria are the presence of at least two bone lesions,
psoriasis or palmoplantar pustulosis, radiological presence
of osteolytic or sclerotic bone lesions, and sterile bone
biopsy with signs of inflammation, fibrosis, and/or sclero-
sis. Minor criteria are normal blood count and good general
state of health, only mild-to-moderate elevation of C-re-
active protein (CRP) and erythrocyte sedimentation rate
(ESR), observation time of[6 months, hyperostosis,
association with other autoimmune diseases apart from
palmoplantar pustulosis or psoriasis, and the presence of
grade I or II relatives with autoimmune or autoinflamma-
tory disease or with CRMO.
Moreover, some authors have proposed a clinical score
to facilitate clinical diagnosis and reduce the number of
invasive procedures or unnecessary bone biopsies [34].
According to the diagnostic criteria, a score\28 indicates
a CRMO diagnosis is unlikely (nominal predictive negative
value of 97%), a score[29 and\38 indicates a possible
diagnosis of CRMO (possibility of CRMO about 80%), and
a score of[39 indicates a very likely diagnosis of CRMO
(nominal predictive positive value of 97%). It is important
to highlight that this score is neither validated nor com-
monly used in clinical practice; however, the score sug-
gests that a positive clinical diagnosis of CMRO may be
made in the absence of biopsy.
Biomarkers for CRMO diagnosis and its follow-up have
been recently proposed; IL-12, monocyte chemoattractant
protein (MCP)-1, and soluble IL (sIL)-2R seem to act as
markers for treatment response. However, these results
need to be confirmed in larger cohorts of patients [35].
5 Treatment
No consensus or guidelines exist on the treatment of
CRMO, and most evidence comes from small case series or
retrospective cohorts. To our knowledge, no randomized
controlled trials relating to CRMO treatments have been
published or are currently enrolling. Table 1 summarizes
the most common treatment options. In the following, we
provide more detail on the drugs used most often in CRMO
treatment.
Fig. 1 a Computed
tomography of the spine.
Coronal plane reconstruction.
Well-defined lytic lesion of left
inferior articular facet of T10
without clear signs of reactive
sclerosis. The inferior articular
facet of T9 appears normal.
b Spine magnetic resonance
imaging. Short time inversion
recovery (STIR) sequence in the
coronal plane. Focal area of
hyperintensity of the left T9–
T10 facet joint, for bone
marrow edema, without thecal
sac compression signs
Fig. 2 Ankle section of T2-short time inversion recovery (STIR)
whole-body magnetic resonance image of a patient with chronic
recurrent multifocal osteomyelitis. The arrow shows hyperintensity of
bone with edema of soft tissues. The patient presented with clinical
involvement of both mandible and ankle
55.1 Non-Steroidal Anti-Inflammatory Drugs
NSAIDs are considered the first-line treatment, with good
responses reported in small case series [36], albeit clinical
remission is not always achieved. The main role of this
treatment is pain control, but NSAIDs may also prevent
bone damage as they are involved in prostaglandin control
[33]. Studies have demonstrated that the rate of clinical
remission with NSAIDs is very wide ranging, from 27 [37]
to 80% [15, 30]. Their mechanism of action mostly relates
to an anti-inflammatory effect on bone; however, which
NSAIDs should be considered the best treatment option is
unclear, and most NSAIDs are used interchangeably.
The NSAIDs most commonly used in CRMO are
ibuprofen, diclofenac [38], indomethacin [39], and
naproxen; however, naproxen is the only NSAID to have
been evaluated prospectively. A study in 37 patients with
CRMO found that 43% of patients experienced a good
response at 1 year of follow-up; improvement was
demonstrated clinically as well as radiologically, and
quality of life also improved [40].
As the action of NSAIDs starts after at least 4 weeks of
therapy, it is important to maintain the treatment for at least
1 month before declaring a failure [38].
5.2 Corticosteroids
Corticosteroids are the most effective anti-inflammatory
drugs; their effects are mediated either by direct binding of
the glucocorticoid/glucocorticoid receptor complex to
glucocorticoid-responsive elements in the promoter region
of genes or by an interaction between this complex and
other transcription factors, particularly activating protein-1
or nuclear factor (NF)-jB. These drugs inhibit many
inflammation-associated molecules such as cytokines,
chemokines, arachidonic acid metabolites, and adhesion
molecules [41].
Oral corticosteroids have been proposed for patients
with CRMO who do not respond to NSAIDs and as a first-
line treatment choice with a very good response rate [42].
The most commonly used corticosteroid preparation is
prednisolone.
5.3 Sulfasalazine and Methotrexate
Sulfasalazine is usually used in patients with associated
inflammatory bowel disease; however, no reports indicate
it works better than do NSAIDs.
Table 1 Most common treatment options for chronic recurrent multifocal osteomyelitis
Treatment options Dosage Length of treatmenta
First-line treatments
NSAIDs
Ibuprofen 30–40 mg/kg/day in 3–4 divided doses 1–3 months
Indometacin 1–2 mg/kg twice daily 1–3 months
Naproxen 5–7.5 mg/kg twice daily 1–3 months
Diclofenac 2–3 mg/kg in 3 divided doses 1–3 months
Corticosteroids
Prednisolone 1–2 mg/kg once daily 15–30 days then tapering
Second-line treatment
Sulfasalazine 10–15 mg/kg 4 times daily 1–3 months
Methotrexate 15–20 mg/m2 once weekly sc 6 months
Bisphosphonates
Pamidronate 1–3 mg/kg/day for 3 consecutive days every 3 monthsb
or
9 months
1 mg/kg/day for 1 day every month 6 months
Anti-TNFa
Infliximab 5 mg/kg/dose. Infusions at time 0, 2, and 6 weeks then every 8 weeks 12 months
Etanercept 0.8 mg/kg/dose/week 6 months
Adalimumab 24 mg/m2 every 2 weeks 6 months
NSAIDs non-steroidal anti-inflammatory drugs, sc subcutaneous, TNF tumour necrosis factor
a Length of treatment is intended as the minimum time to treat patients, but therapy can be prolonged according to clinical status
b First infusion 0.5 mg/kg
6Methotrexate is a well-known treatment in rheumato-
logic conditions, especially in juvenile idiopathic arthritis.
It inhibits purine and pyrimidine synthesis, accounting for
its efficacy in cancer therapy, but many studies have also
focused on the adenosine-mediated anti-inflammatory
effects of methotrexate.
Methotrexate has been used in CRMO but does not seem
to be very effective in this clinical setting [43]. In a cohort
of 70 children with CRMO [44], only 20% of patients
treated with methotrexate experienced clinical remission.
Bisphosphonates and/or TNF-a inhibitors have been
used with variable effects in patients who did not respond
to first-line treatment.
5.4 Bisphosphonates
Although how bisphosphonates exert their anti-inflamma-
tory effect is unclear, it has been suggested that they may
modify the release of proinflammatory cytokines acting on
local effector cells, such as resident macrophages, osteo-
clasts, and fibroblasts [45].
Bisphosphonates have been used in CRMO since 2001
with good clinical effects and durable responses [46].
Simm et al. [47] and Miettunen et al. [48] treated five and
nine patients with CRMO, respectively, with bisphospho-
nate infusions and reported a decrease in pain, symptomatic
improvements, and radiologic improvement in bone
lesions. Although which subsets of patients could benefit
more from treatment with bisphosphonates remains
unclear, studies suggest they are more effective in patients
with multifocal lesions [15], spinal involvement [49],
and—interestingly—mandible involvement [50].
Pamidronate is the most used bisphosphonate, but ner-
idronate has also been demonstrated to be effective [51]. A
randomized trial on the use of pamidronate in patients with
CRMO is ongoing (ClinicalTrials.gov identifier:
NCT02594878), but results are not yet available.
We share the opinions of Stern and Ferguson [4], De
Cunto et al. [51], and Hedrich et al. [33] that bisphospho-
nates should be used in patients when NSAIDs and corti-
costeroids have failed and no systemic feature is present
and possibly as first-line treatment in patients with spinal
involvement [52].
5.5 Tumor Necrosis Factor Inhibition
TNF-a is considered a key protein in inflammation, and
many treatments for autoinflammatory and autoimmune
disorders use TNF-a inhibition. Moreover, TNF has been
implicated in pathological bone resorption, activating
osteoblasts and tissue stromal cells to express the receptor
activator of NF-kB (RANK) ligand (RANKL). In addition,
TNF can act directly on osteoclast precursors, often in
synergy with RANKL, to promote osteoclastogenesis [53].
TNF-a inhibitors have been used in patients with
CRMO. Infliximab was the first biologic used [54], but
etanercept and adalimumab have also been demonstrated to
be effective [55, 56]. They have primarily been used in and
benefitted [15] the roughly\10% of patients who did not
achieve clinical remission with previous treatment. In our
opinion, TNF-a inhibitors should be considered when
bisphosphonates fail or as an alternative when systemic
features (e.g., fever) are present.
5.6 Anti-Interleukin-1 Beta
Given that CRMO is considered an autoinflammatory dis-
ease, some authors suggest that IL-1 inhibition could be a
useful therapeutic approach [57]; however, no evidence of
their efficacy in CRMO has yet been found, except in
patients with inflammatory osteitis secondary to autoin-
flammatory syndromes.
6 Conclusion
CRMO is not completely understood but probably belongs
to the family of autoinflammatory diseases. No diagnostic
criteria have been defined, and diagnosis remains one of
exclusion, sometimes requiring a biopsy. The prognosis is
usually benign, although spine involvement can cause
kyphosis or scoliosis, leading to chronic deformities.
Studies are needed to improve understanding of the role of
possible biomarkers in disease prognosis and to assist
clinicians in choosing the best treatment options. NSAIDs
remain the first-line treatment option for most patients,
followed most frequently by TNF-a inhibitors and bis-
phosphonates as second-line treatments. Given CRMO is
thought to be an autoinflammatory disease, IL-1 inhibition
can also be considered a valid treatment option.
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